2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36)

2019-07-10 NICE官网

2019年7月,英国国家卫生与临床优化研究所 (NICE)发布了类风湿性关节炎TNF-α抑制剂治疗监测指南,指南推荐酶联免疫吸附法(ELISA)进行类风湿性关节炎TNF-α抑制剂的治疗监测。

中文标题:

2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36)

英文标题:

Diagnostics guidance [DG36]:Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

发布机构:

发布日期:

2019-07-10

简要介绍:

2019年7月,英国国家卫生与临床优化研究所 (NICE)发布了类风湿性关节炎TNF-α抑制剂治疗监测指南,指南推荐酶联免疫吸附法(ELISA)进行类风湿性关节炎TNF-α抑制剂的治疗监测。

 

拓展指南:类风湿性关节炎相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36))] GetToolGuiderByIdResponse(projectId=1, id=7adab1c00180117d, title=2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36), enTitle=Diagnostics guidance [DG36]:Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis, guiderFrom=NICE官网, authorId=null, author=, summary=2019年7月,英国国家卫生与临床优化研究所 (NICE)发布了类风湿性关节炎TNF-α抑制剂治疗监测指南,指南推荐酶联免疫吸附法(ELISA)进行类风湿性关节炎TNF-α抑制剂的治疗监测。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Jul 10 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019年7月,英国国家卫生与临床优化研究所 (NICE)发布了类风湿性关节炎TNF-α抑制剂治疗监测指南,指南推荐酶联免疫吸附法(ELISA)进行类风湿性关节炎TNF-α抑制剂的治疗监测。 </P> <P> </P>拓展指南:<strong>与<font color=red>类风湿性关节炎</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=b0c4f1c001e9a274" title="2019 HKSR共识建议:类风湿性关节炎的管理" target=_blank>2019 HKSR共识建议:类风湿性关节炎的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=bed7e1c001e12a8a" title="2018 APLAR建议:类风湿性关节炎的治疗(更新版)" target=_blank>2018 APLAR建议:类风湿性关节炎的治疗(更新版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=d67fd1c0016836cc" title="2018 意大利共识建议:类风湿性关节炎丙型肝炎感染的管理" target=_blank>2018 意大利共识建议:类风湿性关节炎丙型肝炎感染的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c4c9e1c00165282c" title="2018 SFR建议:类风湿性关节炎的管理(更新)" target=_blank>2018 SFR建议:类风湿性关节炎的管理(更新)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=9542f1c001615e3f" title="2018 多学科建议:类风湿性关节炎患者足部问题的诊断和治疗" target=_blank>2018 多学科建议:类风湿性关节炎患者足部问题的诊断和治疗</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E7%B1%BB%E9%A3%8E%E6%B9%BF%E6%80%A7%E5%85%B3%E8%8A%82%E7%82%8E" target=_blank>有关类风湿性关节炎更多指南</a></ul>, tagList=[TagDto(tagId=2259, tagName=类风湿性关节炎), TagDto(tagId=33020, tagName=TNF-α抑制剂), TagDto(tagId=95313, tagName=治疗监测)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12943, appHits=341, showAppHits=7, pcHits=10915, showPcHits=2604, likes=79, shares=16, comments=2, approvalStatus=1, publishedTime=Tue Oct 08 22:21:43 CST 2019, publishedTimeString=2019-07-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Oct 08 22:21:43 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 14:09:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36))])
2019 NICE诊断指南:类风湿性关节炎TNF-α抑制剂治疗监测(DG.36)
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=897987, encodeId=d17e89e9873e, content=🤗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85433204, createdName=Sarah2020cpp, createdTime=Mon Nov 09 15:33:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897984, encodeId=614389e9846e, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85433204, createdName=Sarah2020cpp, createdTime=Mon Nov 09 15:32:51 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2020-11-09 Sarah2020cpp

    🤗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=897987, encodeId=d17e89e9873e, content=🤗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85433204, createdName=Sarah2020cpp, createdTime=Mon Nov 09 15:33:34 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897984, encodeId=614389e9846e, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0e85433204, createdName=Sarah2020cpp, createdTime=Mon Nov 09 15:32:51 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2020-11-09 Sarah2020cpp

    这个不错

    0